antibody

MSD to Buy B-Cell Depletion Therapy from Curon

Major US drugmaker MSD is to pay up to $1.3 billion to acquire CN201, a novel investigational clinical-stage bispecific antibody for the treatment of B-cell associated diseases, from biotechnology company Curon Biopharmaceutical.

News

Leaving the Patent Cliff Behind

Top-Feature

CHEManager International c/o Wiley-VCH GmbH

Upcoming Virtual Events

SCIEX

Capillary Electrophoresis in Biotherapeutic Development: Platform Methods, Fragment Workflows, and ADC Characterization

Global Impact Coalition (GIC)

Siemens Joins the Global Impact Coalition

Evonik Industries AG

Safer, Scalable Pharmaceutical Manufacturing with Flow Chemistry

Citrine

Operationalizing AI in Polymer Development: How Syensqo Is Scaling Impact with the Citrine Platform

Agilent Technologies Inc.

Comprehensive Insights into Antibody–Drug Conjugates (ADC) for Precision Cancer Therapy

Interview

Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

EvaluatePharma

Merck & Co